10-Q: Athira Pharma Shifts Focus to ATH-1105 Amid Losses

Athira Pharma reports reduced losses and operating expenses in Q2 2025, pivoting its R&D focus to ATH-1105 for ALS after its prior lead candidate failed to meet endpoints.

Summary

• Athira Pharma, a clinical-stage biopharmaceutical company, reported a net loss of $16.1 million for the six months ended June 30, 2025, a significant reduction from $53.2 million for the same period in 2024.
• Total operating expenses decreased by 70% to $16.8 million for the six months ended June 30, 2025, down from $55.7 million in the prior year period.
• Research and development expenses saw an 82% decrease, from $43.4 million in H1 2024 to $8.0 million in H1 2025, primarily due to pausing further development of fosgonimeton.
• The company's cash, cash equivalents, and investments stood at $29.8 million as of June 30, 2025, which is estimated to be sufficient to fund operations for at least the next 12 months.
• Athira has an accumulated deficit of $422.3 million as of June 30, 2025, reflecting significant historical losses since inception.
• The company has shifted its primary clinical development focus to ATH-1105 for Amyotrophic Lateral Sclerosis (ALS) after its previous lead candidate, fosgonimeton, failed to meet primary and key secondary endpoints in the Phase 2/3 LIFT-AD clinical trial.
• A Phase 1 clinical trial for ATH-1105 in healthy volunteers was completed in November 2024, showing a favorable safety profile and good tolerability, supporting continued clinical development.
• Athira is exploring strategic alternatives to maximize stockholder value, including potential acquisition, merger, financing, asset sale, or return of capital.
• The company's common stock was transferred to the Nasdaq Capital Market on April 17, 2025, and has until October 13, 2025, to regain compliance with Nasdaq's minimum $1.00 bid price requirement, with a potential reverse stock split being considered.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the failure of the previous lead drug candidate (fosgonimeton) in a pivotal trial, leading to its discontinuation. While cost reductions and a pivot to ATH-1105 are positive, the company still faces significant accumulated losses, a declining cash balance, and a stated need for substantial future funding. The Nasdaq listing issue further adds to the negative outlook, indicating significant challenges ahead despite the reduced burn rate.

Positives

• Net loss significantly decreased by 70% to $16.1 million for the six months ended June 30, 2025, compared to $53.2 million in the prior year.
• Total operating expenses decreased substantially by 70% to $16.8 million for the six months ended June 30, 2025, reflecting successful cost reduction efforts.
• Research and development expenses decreased by 82% due to the strategic decision to pause fosgonimeton development, allowing for focused resource allocation.
• Cash, cash equivalents, and investments of $29.8 million as of June 30, 2025, are projected to fund operations for at least the next 12 months, providing short-term liquidity.
• ATH-1105, the new lead drug candidate for ALS, demonstrated a favorable safety profile and was well-tolerated in its Phase 1 clinical trial, supporting continued development.

Negatives

• The previous lead drug candidate, fosgonimeton, failed to meet primary and key secondary endpoints in the Phase 2/3 LIFT-AD clinical trial, leading to a pause in its development.
• The company has incurred significant accumulated losses, with an accumulated deficit of $422.3 million as of June 30, 2025.
• Cash and cash equivalents decreased from $48.4 million at December 31, 2024, to $19.8 million at June 30, 2025.
• The company is not yet profitable and has no drug products approved for commercial sale, relying heavily on future successful development and commercialization.
• Nasdaq listing compliance issues persist, with the company having until October 13, 2025, to regain compliance with the minimum $1.00 bid price, potentially requiring a reverse stock split.
• Other income, net, decreased by 71% for the six months ended June 30, 2025, due to lower interest income from reduced cash balances.

Risks

• The company is a clinical-stage biopharmaceutical company with a limited operating history and no marketable products, making future success highly uncertain.
• Development of ATH-1105 may never lead to a marketable product, and future trials may not yield sufficient safety, efficacy, and tolerability data.
• The novel therapeutic approach targeting neurotrophic factors through small molecules exposes the company to unforeseen risks due to limited preclinical and clinical data.
• Clinical development is lengthy, expensive, and has an uncertain outcome; results from early, smaller-scale trials may not predict success in large-scale pivotal trials.
• Substantial delays in clinical trials or inability to complete them on expected timelines may occur.
• Limited resources may be expended on a particular drug candidate or indication, failing to capitalize on more profitable or successful opportunities.
• The company has been and may be subject to claims, lawsuits, and investigations, which could divert management attention and incur substantial costs not fully covered by insurance.
• Topline, interim, or preliminary data from clinical trials may change as more patient data become available and are subject to audit and verification, potentially resulting in material changes.
• Reporting of clinical trial data or regulatory submissions/approvals may be delayed or prevented.
• Future acquisitions or strategic partnerships could increase capital requirements, dilute stockholders, incur debt, or assume contingent liabilities.
• Substantial additional funding is required to finance operations, complete development, and commercialize drug candidates; inability to raise funds could force delays or elimination of programs.
• Inability to protect intellectual property or loss of patent protection could adversely affect the ability to prevent competitors from commercializing similar products.
• Significant competition from companies with greater resources and more rapid product development could negatively impact commercial opportunities.
• Loss of key personnel could significantly harm the business, results of operations, and competitive position.
• Failure to regain Nasdaq compliance could lead to delisting, making it harder for investors to sell shares and negatively impacting stock price.
• The market price of common stock has been and may continue to be volatile, potentially resulting in substantial losses for investors.
• Actions by activist stockholders have been and may be disruptive, causing uncertainty about strategic direction.
• The strategic review process may not result in a successful transaction, or any consummated transaction may not be successful or maximize stockholder value.
• The board of directors may decide to pursue dissolution and liquidation, with uncertain amounts available for distribution to stockholders after liabilities are settled.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable; delays or failure to obtain approval would materially impair revenue generation.
• Drug candidates may cause significant adverse events or side effects, inhibiting regulatory approval or market acceptance.
• Obtaining regulatory approval in one jurisdiction does not guarantee approval in others.
• Ongoing regulatory obligations and review post-approval may result in significant additional expense and penalties for non-compliance.
• Potential changes to healthcare laws and regulations, including those aimed at reducing costs, could adversely affect business and profitability.
• Relationships with healthcare professionals and participation in federal programs are subject to fraud and abuse laws, false claims laws, and privacy laws, risking sanctions and penalties.
• Reliance on third parties for nonclinical studies, clinical trials, and manufacturing increases risks of delays, non-compliance, and supply disruptions.
• Even if approved, drug candidates may not achieve adequate market acceptance among physicians, patients, and payors.
• The company has no prior commercialization experience and may lack necessary expertise or resources.
• If the market opportunity for any drug candidate is smaller than believed, revenue may be adversely affected.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Uncertainty regarding insurance coverage and reimbursement status of newly approved products could harm business.
• Risks associated with international marketing, including differing regulatory requirements and economic instability, could adversely affect operations.
• Cybersecurity risks, including security failures or breaches of systems, could lead to loss of data, operational disruptions, and reputational harm.
• Data collection is governed by restrictive regulations (e.g., GDPR, CCPA), increasing compliance costs and potential liability.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future as it advances ATH-1105 through clinical trials, invests in drug development, continues manufacturing activities, hires personnel, protects intellectual property, and operates as a public company. Net losses may fluctuate based on clinical trial timing and R&D expenditures. The company anticipates needing substantial additional funding beyond its current cash runway to complete development and commercialization of ATH-1105 and other drug candidates. It is actively seeking a partner for ATH-1105 development and may pursue equity or debt financings, or other strategic transactions. The company estimates its current cash will fund operations for at least the next 12 months, but this could change based on the strategic alternative review process. The company will remain an emerging growth company until December 31, 2025, and a smaller reporting company as long as certain revenue and public float thresholds are met. It is monitoring its Nasdaq bid price compliance and considering a reverse stock split.

Management Comments

• We are actively reviewing options for partnerships or other arrangements that will allow us to realize the potential of our drug candidates.
• Based on the results of the Phase 1 trial, ATH-1105 demonstrated a favorable safety profile and was well-tolerated in healthy volunteers, supporting continued clinical development.
• Following the readout of topline data from LIFT-AD, we made the determination to explore strategic alternatives focused on maximizing stockholder value.
• We have engaged Cantor Fitzgerald & Co. to act as an advisor in exploring potential strategic alternatives.
• We expect to continue to incur operating losses for the foreseeable future as we continue to advance ATH-1105 and any other drug candidates through preclinical studies and clinical trials.
• We estimate that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months.

Industry Context

The filing highlights the significant challenges inherent in the biopharmaceutical industry, particularly in the field of central and peripheral nervous system degenerative disorders, which has seen very limited success in product development. The company's pivot from fosgonimeton (Alzheimer's) to ATH-1105 (ALS) reflects the high failure rate in neurodegenerative drug development and the need for companies to adapt their pipelines based on clinical outcomes. The emphasis on small molecules and reliance on third-party CMOs and CROs is a common strategy for clinical-stage biopharma companies to manage capital and operational overhead. The ongoing exploration of strategic alternatives, including partnerships or M&A, is also a common response for companies facing significant R&D costs and limited cash runways, especially after a major clinical setback.

Comparison to Industry Standards

• The high rate of attrition in clinical trials, as evidenced by the failure of fosgonimeton in LIFT-AD, is consistent with the industry-wide challenge in developing therapies for complex neurodegenerative diseases like Alzheimer's and ALS. Many companies, such as Biogen with aducanumab (Aduhelm) or Eli Lilly with solanezumab, have faced similar setbacks in Alzheimer's trials, underscoring the difficulty in achieving statistically significant clinical benefits.
• The company's cash runway of 'at least the next 12 months' is a common disclosure for clinical-stage biopharma companies, but it also signals the ongoing need for capital raises, a frequent occurrence in this capital-intensive industry. Companies like Denali Therapeutics or Alector, also focused on neurodegenerative diseases, similarly require substantial and continuous funding for their extensive pipelines.
• The shift to ATH-1105 for ALS, a disease with high unmet medical need, aligns with industry trends where companies target specific, severe indications after broader approaches prove challenging. For example, companies like Amylyx Pharmaceuticals (AMX0035) have recently gained approval for ALS, demonstrating that success, though difficult, is possible in this area.
• The Nasdaq listing compliance issue and consideration of a reverse stock split are common challenges for smaller biotechnology companies whose stock prices may fall below minimum thresholds due to R&D setbacks or broader market sentiment, reflecting a common struggle for smaller cap biotechs to maintain market visibility and liquidity.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings that would reasonably be expected to have a material adverse effect on its business, financial condition, operating results, or cash flows as of June 30, 2025.
• Washington State University (WSU) previously announced a review of prior claims of potential research misconduct involving the company's former chief executive officer's doctoral research at WSU. The company cannot predict the conclusions or effects of this review on its business, reputation, in-licensed patents, or relationship with WSU.

Stakeholder Impact

• **Shareholders:** Face significant uncertainty due to the failure of the previous lead drug candidate, the ongoing strategic review with an uncertain outcome, and the potential for further dilution from future capital raises or a reverse stock split. The Nasdaq listing issue directly impacts their ability to trade shares.
• **Employees:** Experienced a significant workforce reduction (approximately 70%) in September 2024, which could impact morale and future recruiting efforts. Remaining employees are focused on ATH-1105 development.
• **Customers (Future):** Potential patients with ALS may benefit if ATH-1105 successfully completes clinical development and receives regulatory approval, offering a new therapeutic option in a field with limited success.
• **Creditors/Suppliers:** The company's reduced cash position and ongoing need for funding may pose a risk, though the current cash is projected to last 12 months. Reliance on third-party CROs and CMOs means their operations are critical to the company's progress.

Next Steps

• Continue clinical development of ATH-1105 for the potential treatment of ALS.
• Substantially complete preparation activities to enable initiation of a future clinical trial in people living with ALS.
• Explore strategic alternatives focused on maximizing stockholder value, including potential acquisition, merger, financing, asset sale, or return of capital.
• Monitor the closing bid price of common stock and consider available options, including a potential reverse stock split, to regain Nasdaq compliance by October 13, 2025.
• Optimize the manufacturing process for ATH-1105 to support future large-scale and commercial supply.
• Potentially build a commercial infrastructure or collaborate with pharmaceutical companies for sales, marketing, and distribution if drug candidates are approved.

Key Dates

Recommendation

The company is at a critical juncture. While the significant reduction in net loss and operating expenses, coupled with a focused pivot to ATH-1105, are positive signs of cost management and strategic realignment, the underlying challenges remain substantial. The failure of the previous lead candidate, fosgonimeton, highlights the inherent high risk in neurodegenerative drug development. The current cash runway, while sufficient for 12 months, necessitates substantial future capital raises, which could lead to significant shareholder dilution. The ongoing Nasdaq compliance issue and the exploration of strategic alternatives introduce considerable uncertainty regarding the company's future structure and valuation. A 'hold' recommendation is appropriate for investors who acknowledge the high-risk, high-reward nature of clinical-stage biopharma, believe in the potential of ATH-1105 for ALS, and are willing to await the outcome of the strategic review and further clinical data. However, this is a highly speculative investment, and a 'sell' might be considered by those with lower risk tolerance given the past clinical failure and the significant financial uncertainties.

Keywords

Biopharmaceutical, Neurodegenerative diseases, ALS, ATH-1105, Clinical-stage, SEC filing, 10-Q, Financial results, Research and development, Strategic alternatives, Nasdaq compliance, Drug development, HGF system, Neurotrophic factors